Phio Pharmaceuticals shares are trading higher. The company announced it will present data on the INSTAYL compound PH-894 at ASGCT's 2024 cancer conference.
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals shares are trading higher following the announcement that the company will present data on its INSTAYL compound PH-894 at the ASGCT's 2024 cancer conference.
October 16, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phio Pharmaceuticals shares are experiencing an upward trend due to the announcement of presenting data on their compound PH-894 at a major cancer conference.
The announcement of presenting data at a significant conference can boost investor confidence and interest in the company's research, leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100